 Clinical-stage biopharmaceutical company GH Research PLC NASDAQ: GHRS announced positive results from recent clinical trials of its leading 5-MeO-DMT formula, a therapy candidate for patients suffering from treatment-resistant depression TRD. The Ireland-based company, which this year announced a capital raise of 315 million, is focused exclusively on research around the psychoactive molecule 5-MeO-DMT to treat depression, a condition that affects many millions of people around the world. 